The short version of tuftsin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Modeled on tuftsin |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues |
| Approximate molecular mass | Around 750 Da | Depends on counter-ion and hydration |
| Common forms | Lyophilized powder | Also described as aqueous solution |
| Primary origin of research | Russian laboratories | Mid-1990s onward |
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
==== Renewed clashes ==== The conflict between Houthis and Salafis in Saada Governorate was renewed in October and November. Saada government officials accused Houthi fighters of attacking a Salafi mosque in Dammaj in an attempt to drive the Sunnis out, while the Houthis accused the Salafis of using the religious institute as a staging ground for foreign Sunni fighters. The government attempted to intervene to stop the fighting. Sectarian fighting in Al Jawf Governorate lasted throughout the year. Dhamar Governorate also saw clashes between the Houthis and Salafis toward the end of the year.
=== Stress/ Hypothalamic-pituitary-adrenal (HPA) axis === GHSR1A, Ghrelin's endogenous receptor, is expressed within the hypothalamus including the arcuate nucleus, but not in the paraventricular nucleus (PVN) where ghrelin has been found to indirectly affect HPA axis function via neighboring corticotropin releasing hormone (CRH) neurons. Studies regarding how ghrelin affects cortisol and adrenocorticotropic hormone (ACTH) secretion along with how cortisol and ACTH levels affect ghrelin are inconsistent as different psychological and physical stressors within in-vivo studies have produced a myriad of results as the underlying mechanisms are still not understood well.
== Current state of the industry == A tablet counter has become a standard in more than 30,000 sites in 35 countries (as of 2010) (including many non-pharmacy sites, such as manufacturing facilities that use a counting machine as a check for small items). During the 1990s through 2012, numerous new pharmacy automation products came to market. During this timeframe, counting technologies, robotics, workflow management software, and interactive voice recognition (IVR) systems for retail (both chain and independent), outpatient, government, and closed-door pharmacies (mail order and central fill) were all introduced. Additionally, the concept of scalability - of migrating from an entry-level product to the next level of automation (e.g., counting technology to robotics) - was introduced and subsequently launched a new product line in 1997. Pharmacists are transitioning to automation. As the industry evolves and customer expectations grow, automation is emerging as necessity rather than luxury. Especially for independent pharmacies, automation becomes a means of keeping up with the competition of large chain pharmacies.
== Applications == Orthogonal protecting group strategies are important in the synthesis of complex organic molecules, including natural products, pharmaceutical drugs, and biologically active compounds. They are particularly useful in peptide synthesis, where multiple amino acid side chains require selective protection during assembly. In solid-phase peptide synthesis, the Fmoc strategy relies on orthogonal protection, allowing repeated cycles of amino acid addition while maintaining control over the growing peptide chain. Orthogonal approaches are also used in carbohydrate chemistry, nucleoside synthesis, and chemical biology, where precise control over molecular transformations is required.
== Medical uses == Amitriptyline/chlordiazepoxide is used for the treatment of moderate to severe depression associated with moderate to severe anxiety. It has shown to be more effective in treating symptoms of anxiety, irritability, and hostility in patients with comorbid depression and anxiety than amitriptyline alone. It also has a quicker onset time than either amitriptyline or chlordiazepoxide on their own.
Sources: en.wikipedia.org
It was later determined that the Act-1 monoclonal antibody reacted with an α4β7 integrin that was subsequently shown to interact with a gut-associated addressin, MadCAM. Early work with Dr. Bruce Yacyshyn showed differential expression in inflammatory bowel disease. Dr. Lazarovits isolated the antibody to produce the murine homologue MLN0002 which he licensed with the Massachusetts General Hospital to Millennium Pharmaceuticals of Boston for further development. Scientists at LeukoSite realized the potential of this antibody to treat inflammatory bowel disease, and this company was eventually acquired by Millennium which took an exclusive license to the cell line from Massachusetts General Hospital. In vivo proof of concept ultimately led to the decision to humanize the antibody and move it into clinical trials as "Vedolizumab". In addition to its reactivity to gut-associated lymphoid tissues, Act-1 antibody also stains large numbers of lymphocytes in rheumatoid synovium, and has been shown by Dr. A. A. Ansari of Emory University to prevent or delay onset of AIDS in a monkey-model of Simian Immunodeficiency Virus-induced AIDS. Thus, reactivity with this antibody may show widespread applicability in inflammatory processes of diverse etiologies.
=== Partnerships and investments from US companies === Also in July, the UK government signed a deal with OpenAI to use its products in public services to increase productivity. As part of the 2025 Tech Prosperity Deal between the UK and the US, several American companies are investing tens of billions of pounds in British AI infrastructure.
The white shark has a stocky, torpedo-shaped body with a short, cone-shaped snout. Its long gill slits do not reach around the head. It has a large triangular first dorsal fin, which partly lines up with the pectoral fins, and a tiny second dorsal fin. The tail fin has two lobes of similar size and a single ridge or keel, and the anal fin is tiny. The white shark has a countershaded coloration for camouflage; being dark on top, usually blue-gray or gray-brown, with a white underside. It also has black tips on the underside of the pectoral fins. There is evidence that the species can change pigments, adding dark pigment or melanin to blotches of white over the course of months. The skin is covered in dermal denticles (tooth-like scales), which are proportionally smaller than in other sharks and have a three-to-five-ridged surface, with each ridge having tips that point backwards.
The idea of the great chain, as well as the derived "missing link", was abandoned in early 20th-century science, as the notion that embryonic development recapitulates "lower" forms was abandoned in biology, to be replaced by an evolutionary tree supplemented by horizontal gene transfer, as well as more complex web structures. The idea of a certain sequence from lower to higher complexity and fitness is still popular, as is the idea of progress in biology.
== History == IDLO was founded in 2016 to create tasty, healthy, and convenient meals for mountain hiking and expeditions. IDLO was the first company in Ukraine to package freeze-dried meals in doypacks, allowing users to prepare and consume meals directly from the pouch without the need for dishes. Its range of main courses is produced using freeze-drying technology at its facility, in accordance with food safety management systems compliant with ISO 22000/HACCP standards. Since 2020, the company has been supplying freeze-dried meals to the Ukrainian Antarctic research station Academician Vernadsky. The company's product line includes over 40 items, such as breakfasts, lunches, dinners, snacks, and beverages. Products are available in retail chains including Gorgany, Decathlon, and Intersport/Epicentr.
Sources: en.wikipedia.org
Fasting, whether it be a planned fast or overnight fast, as there is a long period of time without glucose intake Exercising more than usual as it leads to more use of glucose, especially by the muscles Drinking alcohol, especially when combined with diabetic medications, as alcohol inhibits glucose production Kidney disease, as insulin cannot be cleared out of circulation well
=== Cardiovascular system === Women are less impacted by heart disease due to vasculo-protective action of estrogen which helps in preventing atherosclerosis. It also helps in maintaining the delicate balance between fighting infections and protecting arteries from damage thus lowering the risk of cardiovascular disease. During pregnancy, high levels of estrogens increase coagulation and the risk of venous thromboembolism. Estrogens have been shown to upregulate the peptide hormone adropin, increase platelet adhesiveness, and increase the circulating level of coagulation factors 2, 7, 9, and 10, as well as plasminogens. They also decrease antithrombin III, which suppresses parts of the coagulation system.
===== Pharmacodynamics ===== The melanocortin receptor agonist proposes to activate multiple receptor subtypes nonselectively, with the highest affinity with MC1R, then MC4R, MC3R, MC5R, and MC2R receptors. As MC4R receptors are present on neurons in the central nervous system, a function in modulating brain pathways is suggested, albeit a precise mechanism remains unknown.
== History == The first Upper Crust opened in 1986 by Travellers Fare, the catering division of British Rail, in London Waterloo Station. The chain is now owned by SSP. During the COVID-19 pandemic in the United Kingdom, SSP announced it was cutting 5,000 UK jobs across its chains, including Upper Crust and Caffè Ritazza, as part of a restructuring aimed at keeping the company afloat.
Sources: en.wikipedia.org
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.
It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.
No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.